Answers are grounded in this paper and cite their sources.
Type 1 Diabetes Mellitus (T1DM) results from the autoimmune destruction of insulin-producing pancreatic cells. Despite advances in our understanding of both the pathogenesis and management of diabetes and treatment options, which mainly include injectable insulin and whole pancreas transplant, these advancements remain unsatisfactory and only a small portion of patients achieve their glycemic goals. Insulin gene therapy refers to the development of cell substitutes by introducing an insulin producing gene into endogenous cell populations that do not normally produce insulin. This strategy has the promise to overcome the limitations of current treatments. Here, we present an overview of the history of insulin gene therapy and review current achievements. We also briefly discuss areas for improvement and potential future directions.
No takes yet. Share an insight, caveat, or question.
Akcan et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: